tuneTypical Dose
gram-range in clinical monitoring settings
Supplement
D-Serine
D-Serine
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
weeks in clinical contexts
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
D-Serine is an amino acid neuromodulator that influences NMDA receptor signaling. It is used in research contexts for cognition and negative symptom support.
Small trials, largely in neuropsychiatric populations, suggest possible improvements in negative symptoms or cognitive measures when NMDA signaling is targeted. Evidence is inconsistent and not established for healthy users. Minority research explores effects on sleep architecture and neuroprotection in animal models. Headache, agitation, and interactions with psychiatric medications are possible.
NMDA co-agonist effects are biologically plausible but translation to healthy cognition remains limited.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Biological signal on NMDA pathway engagement
- No robust cognitive enhancement in healthy adults
Secondary Outcomes
- Mood/symptom signal in selected clinical cohorts
- Renal safety and tolerability uncertainty
Safety
Contraindications and Interactions
Contraindications
- Kidney disease
- Severe psychiatric instability
Side effects
- Nausea and headache
- Mood variability
- Renal intolerance (rare but relevant)
Interactions
- CNS-active prescriptions
- Unsupervised nootropic combinations
Avoid if
- CKD/renal impairment
- Mood-unstable states
Evidence
Study-level References
d-serine-SRC-001Controlled clinical research (psychiatric/neurologic cohorts)
Human clinical exploration of D-serine in cognitive/symptom scales
Population: Non-healthy clinical populations
Dose protocol: Oral D-serine dosing within clinical trial conditions
Key findings: Some directionally favorable signals in select protocols.
Notes: Limited generalization to healthy user scenarios.
Paper content
Some directionally favorable signals in select protocols.
d-serine-SRC-002Review of human clinical and adverse-event datasets
Safety and tolerability synthesis for D-serine human use
Population: Clinical trial participants
Dose protocol: Variable clinical dosing
Key findings: No conclusive self-directed nootropic proof.
Notes: Monitoring intensity differs widely from over-the-counter conditions.
Paper content
No conclusive self-directed nootropic proof.
d-serine-SRC-003Network meta-analysis of randomized controlled trials.
Sourceopen_in_newLiang CW, Cheng HY, Tseng MCM. Augmentation with glutamatergic modulators for schizophrenia: A network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2025. doi:10.1016/j.pnpbp.2025.111495. PMID:40945815.
Population: 12,339 patients with schizophrenia across 148 randomized controlled trials.
Dose protocol: D-serine 2000 to 4000 mg/day as adjunct to antipsychotics, pooled across 148 RCTs (12,339 patients total)
Key findings: D-serine showed moderate to high certainty benefit in at least one schizophrenia symptom domain but ranked below sarcosine and benzoate for most outcomes.
Notes: Largest network analysis contextualizing D-serine against other NMDA-pathway modulators. Confirms a real but modest signal.
Paper content
This network meta-analysis compared 12 glutamatergic modulators as adjuncts to antipsychotics across 148 RCTs and 12,339 patients with schizophrenia. D-serine at 2000 to 4000 mg/day demonstrated moderate to high certainty benefits in at least one symptom domain. Among all agents, piracetam showed the largest total psychopathology improvement (SMD -0.94), benzoate was strongest for positive symptoms (SMD -0.43), memantine for negative symptoms (SMD -0.64), and the sarcosine-benzoate combination for cognitive function. D-serine ranked below sarcosine and benzoate for most outcomes but remained a credible glutamatergic augmentation option. This is the largest network analysis placing D-serine in context against other NMDA-pathway modulators.